Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T84581
|
||||
| Former ID |
TTDS00276
|
||||
| Target Name |
Thioredoxin reductase, cytoplasmic
|
||||
| Gene Name |
TXNRD1
|
||||
| Synonyms |
Cytosolic thioredoxin reductase; TR; TR1; Thioredoxin reductase; TrxR; TXNRD1
|
||||
| Target Type |
Successful
|
||||
| Disease | Cancer [ICD9: 140-229; ICD10: C00-C96] | ||||
| Malaria [ICD10: B54] | |||||
| BioChemical Class |
Oxidoreductases acting on a sulfur group of donors
|
||||
| Target Validation |
T84581
|
||||
| UniProt ID | |||||
| EC Number |
EC 1.8.1.9
|
||||
| Sequence |
MGCAEGKAVAAAAPTELQTKGKNGDGRRRSAKDHHPGKTLPENPAGFTSTATADSRALLQ
AYIDGHSVVIFSRSTCTRCTEVKKLFKSLCVPYFVLELDQTEDGRALEGTLSELAAETDL PVVFVKQRKIGGHGPTLKAYQEGRLQKLLKMNGPEDLPKSYDYDLIIIGGGSGGLAAAKE AAQYGKKVMVLDFVTPTPLGTRWGLGGTCVNVGCIPKKLMHQAALLGQALQDSRNYGWKV EETVKHDWDRMIEAVQNHIGSLNWGYRVALREKKVVYENAYGQFIGPHRIKATNNKGKEK IYSAERFLIATGERPRYLGIPGDKEYCISSDDLFSLPYCPGKTLVVGASYVALECAGFLA GIGLDVTVMVRSILLRGFDQDMANKIGEHMEEHGIKFIRQFVPIKVEQIEAGTPGRLRVV AQSTNSEEIIEGEYNTVMLAIGRDACTRKIGLETVGVKINEKTGKIPVTDEEQTNVPYIY AIGDILEDKVELTPVAIQAGRLLAQRLYAGSTVKCDYENVPTTVFTPLEYGACGLSEEKA VEKFGEENIEVYHSYFWPLEWTIPSRDNNKCYAKIICNTKDNERVVGFHVLGPNAGEVTQ GFAAALKCGLTKKQLDSTIGIHPVCAEVFTTLSVTKRSGASILQAGCUG |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Fotemustine | Drug Info | Approved | Cancer | [1] |
| Inhibitor | 3-formyl-4-phenyl-1,2,5-oxadiazole 2-oxide | Drug Info | [2] | ||
| 4,6-dinitrobenzo[c][1,2,5]thiadiazole | Drug Info | [3] | |||
| 5,8-Dihydroxy-1,4-naphthoquinone | Drug Info | [4] | |||
| Bis(2,4-dinitrophenyl)sulfane | Drug Info | [3] | |||
| Flavin-Adenine Dinucleotide | Drug Info | [5] | |||
| Fotemustine | Drug Info | [5] | |||
| Spermidine | Drug Info | [5] | |||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | J Med Chem. 2009 Oct 22;52(20):6474-83.Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. | ||||
| REF 3 | Bioorg Med Chem Lett. 2006 Apr 15;16(8):2283-92. Epub 2006 Feb 3.Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents. | ||||
| REF 4 | Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10. Epub 2007 Mar 6. | ||||
| REF 5 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.